Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00920959 · ClinicalTrials.gov registry record · Phase 3
Advair Pediatric Once-Daily
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 908
- Enrollment target
NCT00920959: Completed Phase 3 study, sponsored by GlaxoSmithKline.
NCT00920959 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 908 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (18% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00920959, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 908 participants
- Enrollment target
Study Summary
To demonstrate if once-daily dosing of ADVAIR 100/50 once-daily has superior efficacy and comparable safety compared with FP 100mcg once-daily in pediatric subjects 4 to 11 years of age with asthma.
Interventions
- DRUG Placebo
- DRUG FP 100mcg
- DRUG FSC 100/50mcg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 908 participants |
| Start Date | 2001-11 |
| Est. Completion | 2004-01 |
| Phase | Phase 3 |
What the finished NCT00920959 record still lists
NCT00920959 is an interventional study that assigns participants to a tested intervention. The registered 908 participants enrollment target is mid-sized for trials with a published cap, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (18% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00920959 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00920959 about?
NCT00920959 is a clinical study titled "Advair Pediatric Once-Daily". To demonstrate if once-daily dosing of ADVAIR 100/50 once-daily has superior efficacy and comparable safety compared with FP 100mcg once-daily in pediatric subjects 4 to 11 years of age with asthma.
What is the current status of trial NCT00920959?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 908 participants. The study started on 2001-11. Estimated completion is 2004-01.
What interventions are being tested in trial NCT00920959?
The interventions under investigation include: Placebo (DRUG), FP 100mcg (DRUG), FSC 100/50mcg (DRUG).
Who is sponsoring clinical trial NCT00920959?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00920959's enrollment target sits among peer trials
908 347th of 2000 higher than 1,654 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05658497 · 908 participants
Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate)
- NCT06216548 · 909 participants · NA
E-PRIME For Children With Medical Complexity
- NCT06131840 · 914 participants · Phase 1
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
- NCT05769777 · 901 participants · Phase 2
Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia